Document And Entity Information
Document And Entity Information | 9 Months Ended |
Sep. 30, 2019 | |
Document Information [Line Items] | |
Entity Registrant Name | BeyondSpring Inc. |
Entity Central Index Key | 0001677940 |
Current Fiscal Year End Date | --12-31 |
Document Type | 6-K |
Document Period End Date | Sep. 30, 2019 |
Document Fiscal Year Focus | 2019 |
Document Fiscal Period Focus | Q3 |
Amendment Flag | false |
Audited Consolidated Balance Sh
Audited Consolidated Balance Sheet as of December 31, 2018 and Unaudited Interim Condensed Consolidated Balance Sheet as of September 30, 2019 - USD ($) $ in Thousands | Sep. 30, 2019 | Dec. 31, 2018 |
Current assets: | ||
Cash and cash equivalent | $ 24,678 | $ 3,889 |
Advances to suppliers | 5,201 | 1,209 |
Due from related parties | 481 | |
Prepaid expenses and other current assets | 362 | 292 |
Total current assets | 30,241 | 5,871 |
Noncurrent assets: | ||
Property and equipment, net | 217 | 282 |
Operating lease right-of-use assets | 2,704 | |
Other noncurrent asset | 978 | 910 |
Total noncurrent assets | 3,899 | 1,192 |
Total assets | 34,140 | 7,063 |
Current liabilities: | ||
Accounts payable | 1,948 | 9,586 |
Accrued expenses | 4,790 | 5,495 |
Current portion of operating lease liabilities | 542 | |
Other current liabilities | 1,089 | 1,364 |
Total current liabilities | 8,369 | 16,445 |
Noncurrent liabilities: | ||
Long-term loans | 1,399 | |
Operating lease liabilities | 2,091 | |
Total noncurrent liabilities | 3,490 | |
Total liabilities | 11,859 | 16,445 |
Equity (Deficit): | ||
Ordinary shares ($0.0001 par value; 500,000,000 shares authorized; 23,184,612 and 25,964,190 shares issued and outstanding as of December 31, 2018 and September 30, 2019, respectively) | 3 | 2 |
Additional paid-in capital | 223,019 | 170,950 |
Accumulated deficit | (202,772) | (178,760) |
Accumulated other comprehensive income | 225 | 42 |
Total BeyondSpring Inc.’s shareholder’s (deficit) equity | 20,475 | (7,766) |
Noncontrolling interests | 1,806 | (1,616) |
Total (deficit) equity | 22,281 | (9,382) |
Total liabilities and (deficit) equity | $ 34,140 | $ 7,063 |
Audited Consolidated Balance _2
Audited Consolidated Balance Sheet as of December 31, 2018 and Unaudited Interim Condensed Consolidated Balance Sheet as of September 30, 2019 (Parentheticals) - $ / shares | Sep. 30, 2019 | Dec. 31, 2018 |
Ordinary shares, par value (in dollars per share) | $ 0.0001 | $ 0.0001 |
Ordinary shares, authorized (in shares) | 500,000,000 | 500,000,000 |
Ordinary shares, issued (in shares) | 25,964,190 | 23,184,612 |
Ordinary shares, outstanding (in shares) | 25,964,190 | 23,184,612 |
Unaudited Interim Condensed Con
Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss for the Three and Nine Months Ended September 30, 2018 and 2019 - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2019 | Sep. 30, 2018 | Sep. 30, 2019 | Sep. 30, 2018 | |
Revenue | $ 0 | |||
Operating expenses | ||||
Research and development | (7,230) | (14,123) | (18,762) | (39,191) |
Selling, general and administrative | (2,474) | (1,528) | (6,260) | (3,644) |
Loss from operations | (9,704) | (15,651) | (25,022) | (42,835) |
Foreign exchange loss, net | (131) | (321) | (127) | (449) |
Interest expense | (46) | (186) | ||
Interest income | 57 | 77 | 64 | 205 |
Other income | 316 | |||
Loss before income tax | (9,824) | (15,895) | (25,271) | (42,763) |
Income tax benefit | 0 | 0 | 0 | 0 |
Net loss | (9,824) | (15,895) | (25,271) | (42,763) |
Less: Net loss attributable to noncontrolling interests | (457) | (965) | (1,259) | (2,011) |
Net loss attributable to BeyondSpring Inc. | $ (9,367) | $ (14,930) | $ (24,012) | $ (40,752) |
Net loss per share | ||||
Basic and diluted (in dollars per share) | $ (0.37) | $ (0.65) | $ (1.01) | $ (1.81) |
Weighted-average shares outstanding | ||||
Basic and diluted (in shares) | 25,309,776 | 22,951,635 | 23,819,453 | 22,547,990 |
Other comprehensive loss, net of tax of nil: | ||||
Foreign currency translation adjustment gain | $ 113 | $ 167 | $ 144 | $ 271 |
Comprehensive loss | (9,711) | (15,728) | (25,127) | (42,492) |
Less: Comprehensive loss attributable to noncontrolling interests | (494) | (953) | (1,298) | (1,977) |
Comprehensive loss attributable to BeyondSpring Inc. | $ (9,217) | $ (14,775) | $ (23,829) | $ (40,515) |
Unaudited Interim Condensed C_2
Unaudited Interim Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2018 and 2019 - USD ($) $ in Thousands | 9 Months Ended | |
Sep. 30, 2019 | Sep. 30, 2018 | |
Operating activities: | ||
Net loss | $ (25,271) | $ (42,763) |
Adjustments to reconcile net loss to net cash from operating activities: | ||
Share-based compensation | 1,750 | 6,041 |
Depreciation expenses | 61 | 29 |
Other income from government grant | (307) | |
Changes in operating assets and liabilities: | ||
Advances to suppliers | (3,992) | (321) |
Due from related parties | 481 | |
Prepaid expenses and other current assets | (89) | (209) |
Operating lease right-of-use assets | 484 | |
Other noncurrent assets | (68) | (296) |
Accounts payable | (7,638) | (18) |
Accrued expenses | (705) | 6,137 |
Operating lease liabilities | (536) | |
Other current liabilities | 43 | 72 |
Net cash used in operating activities | (35,480) | (31,635) |
Investing activities: | ||
Acquisitions of property and equipment | (4) | (97) |
Proceeds from maturity of short-term investments | 3,074 | |
Net cash provided by (used in) investing activities | (4) | 2,977 |
Financing activities: | ||
Proceeds from issuance of ordinary shares, net of underwriting discounts and commissions | 44,957 | 14,000 |
Capital contributions from noncontrolling interests | 10,083 | |
Payment of offering costs | (318) | (255) |
Proceeds from loans | 2,986 | |
Proceeds from related party borrowings | 3,328 | |
Repayment of loans | (1,493) | |
Repayment of related party borrowings | (3,328) | |
Net cash provided by financing activities | 56,215 | 13,745 |
Effect of foreign exchange rate changes, net | 58 | 271 |
Net (decrease) increase in cash and cash equivalents | 20,789 | (14,642) |
Cash and cash equivalent at beginning of period | 3,889 | 27,481 |
Cash and cash equivalent at end of period | $ 24,678 | $ 12,839 |
Note 1 - Nature of the Business
Note 1 - Nature of the Business and Basis of Preparation | 9 Months Ended |
Sep. 30, 2019 | |
Notes to Financial Statements | |
Nature of Operations [Text Block] | 1. Nature of the business and basis of preparation BeyondSpring Inc. (the “Company”) was incorporated in the Cayman Islands on November 21, 2014. On May 21, 2019, $30,000 July 2019, 620,753 $13,023. On June 14, 2019 July 3, 2019, 9th $14,537 RMB100,000 4.76% $10,083 RMB70,000 On June 25, 2019, As at September 30, 2019, Name of company Place of incorporation Date of incorporation Percentage of ownership by the Company Principal activities BeyondSpring Delaware, Pharmaceuticals Inc. United States of America (“U.S.”) June 18, 2013 100% Clinical trial activities BeyondSpring Ltd. BVI December 3, 2014 100% Holding company BeyondSpring (HK) Limited Hong Kong January 13, 2015 100% Holding company Wanchun Biotechnology Limited BVI April 1, 2015 100% Holding company Wanchun Biotechnology The People’s Republic of China (Shenzhen) Ltd. (“PRC”) April 23, 2015 100% Holding company Wanchunbulin PRC May 6, 2015 57.97% Clinical trial activities BeyondSpring Pharmaceuticals Australia PTY Ltd. (“BeyondSpring Australia”) Australia March 3, 2016 100% Clinical trial activities Beijing Wanchun Pharmaceutical Technology Ltd. (“Beijing Wanchun”) PRC May 21, 2018 57.97% Clinical trial activities SEED BVI June 25, 2019 100% Holding company The accompanying unaudited interim condensed consolidated balance sheet as of September 30, 2019, three nine September 30, 2018 2019, nine September 30, 2018 2019, December 31, 2018. not In the opinion of management, the accompanying unaudited interim condensed consolidated financial statements contain all normal recurring adjustments necessary to present fairly the financial position, operating results and cash flows of the Company for each of the periods presented. The results of operations for the three nine September 30, 2019 not 2019. December 31, 2018 not December 31, 2018. |
Note 2 - Summary of Significant
Note 2 - Summary of Significant Accounting Policies | 9 Months Ended |
Sep. 30, 2019 | |
Notes to Financial Statements | |
Significant Accounting Policies [Text Block] | 2. Summary of significant accounting policies Basis of consolidation The unaudited interim condensed consolidated financial statements include the financial statements of the Company and its subsidiaries. All significant intercompany transactions and balances between the Company and its subsidiaries are eliminated upon consolidation. Going concern According to Accounting Standards Codification (“ASC”) 205 40, Presentation of Financial Statements - Going Concern 205 40” one not not 1 one 2 one The Company has incurred operating losses and negative cash flows from operations since inception. To date, the Company has no $25,271 nine September 30, 2019 $202,772 September 30, 2019. $35,480 nine September 30, 2019. September 30, 2019, $21,872 $24,678 In October November 2019, $25,771 Based on the Company’s cash on hand at September 30, 2019 October November 2019 not one Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these financial statements include, but are not Government grants Government grants relating to assets are recognized in the consolidated balance sheets upon receipt and amortized as other income over the weighted average useful life of the related assets. Government grants relating to income that involves no Fair value measurements The Company applies ASC 820, Fair Value Measurements and Disclosures 820” 820 ASC 820 three • Level 1— • Level 2— • Level 3— no ASC 820 three 1 2 3 Financial instruments of the Company primarily include cash, due from related parties, due to related parties, accounts payable and long-term loans. Except for the long-term loans, the carrying values of these financial instruments approximated their fair value due to their short term nature as of December 31, 2018 September 30, 2019. As of September 30, 2019, $1,399, $1,338. 2 Leases The Company determines if an arrangement is a lease at inception. The Company has lease agreements with lease and non-lease components, which are accounted for as a single lease component based on the Company’s policy election to combine lease and non-lease components for its leases. Leases are classified as operating or finance leases in accordance with the recognition criteria in ASC 842 20 25. September 30, 2019. not At the commencement date of a lease, the Company determines the classification of the lease based on the relevant factors present and records right-of-use (“ROU”) assets and lease liabilities. ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. ROU assets and lease liabilities are calculated as the present value of the lease payments not not not may Operating leases are included in operating lease right-of-use assets and lease liabilities on the condensed consolidated balance sheets. Lease liabilities that become due within one Leases with an initial lease term of 12 not Recent accounting pronouncements New accounting standard which have been implemented In February 2016, No. 2016 2, Leases 2018 1, Land Easement Practical Expedient 2018 10, Codification Improvements to Topic 842, 2016 2; 2018 11, Leases (Topic 842 2018 20, Leases (Topic 842 2019 1, Leases (Topic 842 12 December 15, 2018, not The Company adopted the new standard effective January 1, 2019 not not $3,169, $3,188 $19. not In June 2018, 2018 7, Compensation—Stock Compensation (Topic 718 2018 7” 718 718 December 15, 2018. no Impact of adopted accounting standards The cumulative effect of changes made to the Company’s condensed consolidated balance sheet as of January 1, 2019 Balance at Adjustments Balance at December 31, due to January 1, 2018 Lease ASUs 2019 $ $ $ Assets: Prepaid expenses and other current assets 292 (19 ) 273 Operating lease right-of-use assets - 3,188 3,188 Liabilities: Current portion of operating lease liabilities - 605 605 Operating lease liabilities - 2,564 2,564 |
Note 3 - Property and Equipment
Note 3 - Property and Equipment, Net | 9 Months Ended |
Sep. 30, 2019 | |
Notes to Financial Statements | |
Property, Plant and Equipment Disclosure [Text Block] | 3. Property and equipment, net Property and equipment consist of the following: December 31, September 30, 2018 2019 $ $ (Unaudited) Office equipment 143 145 Laboratory equipment 111 112 Motor vehicles 23 23 Leasehold improvements 109 102 386 382 Less: accumulated depreciation (104 ) (165 ) Property and equipment, net 282 217 Depreciation expenses for the three nine September 30, 2018 $9 $29, three nine September 30, 2019 $21 $61, |
Note 4 - Long-term Loans
Note 4 - Long-term Loans | 9 Months Ended |
Sep. 30, 2019 | |
Notes to Financial Statements | |
Long-term Debt [Text Block] | 4. Long-term loans On January 21, 2019, $1,493 RMB10,000 third 15% April 20, 2019, October 20, 2020 April 21, 2019. August 15, 2019. On March 28, 2019, three $1,493 RMB10,000 120.0% three March 28, 2022. |
Note 5 - Related Party Transact
Note 5 - Related Party Transactions | 9 Months Ended |
Sep. 30, 2019 | |
Notes to Financial Statements | |
Related Party Transactions Disclosure [Text Block] | 5. Related Party Transactions Loan to a related party In December 2018, $481 $100 February 2019 April 2019. Loan from related parties In March 2019, $350 August 13, 2019. On April 26, 2019, $1,000, 15% $1,000 April 2019. August 15, 2019. On July 15, 2019, one $1,978 RMB13,600 July August 2019. |
Note 6 - Income Taxes
Note 6 - Income Taxes | 9 Months Ended |
Sep. 30, 2019 | |
Notes to Financial Statements | |
Income Tax Disclosure [Text Block] | 6. Income taxes There is no three nine September 30, 2018 2019. The Company recorded a full valuation allowance against deferred tax assets for all periods presented. No |
Note 7 - Equity (Deficit)
Note 7 - Equity (Deficit) | 9 Months Ended |
Sep. 30, 2019 | |
Notes to Financial Statements | |
Stockholders' Equity Note Disclosure [Text Block] | 7. Equity (deficit) The movement of equity (deficit) is as follows: BeyondSpring Inc.’s shareholders Accumulated Additional other Non Total Ordinary share paid-in Accumulated comprehensive Subtotal controlling equity Shares Amount capital deficit (loss) gain interests (deficit) $ $ $ $ $ $ $ Balances at January 1, 2019 (audited) 23,184,612 2 170,950 (178,760 ) 42 (7,766 ) (1,616 ) (9,382 ) Issuance of ordinary shares 2,679,578 1 44,956 - - 44,957 - 44,957 Capital contribution from noncontrolling interests - - 5,941 - - 5,941 4,142 10,083 Share-based compensation 100,000 - 1,750 - - 1,750 - 1,750 Capital contribution shared by noncontrolling interests - - (578 ) - - (578 ) 578 - Foreign currency translation adjustment gain (loss) - - - - 183 183 (39 ) 144 Net loss - - - (24,012 ) - (24,012 ) (1,259 ) (25,271 ) Balances at September 30, 2019 (unaudited) 25,964,190 3 223,019 (202,772 ) 225 20,475 1,806 22,281 Balances at January 1, 2018 (audited) 22,530,702 2 151,147 (123,891 ) (182 ) 27,076 960 28,036 Issuance of ordinary shares 739,095 - 13,245 - - 13,245 - 13,245 Share-based compensation (95,000 ) - 6,039 - - 6,039 2 6,041 Foreign currency translation adjustment gain - - - - 237 237 34 271 Net loss - - - (40,752 ) - (40,752 ) (2,011 ) (42,763 ) Balances at September 30, 2018 (unaudited) 23,174,797 2 170,431 (164,643 ) 55 5,845 (1,015 ) 4,830 |
Note 8 - Restricted Net Assets
Note 8 - Restricted Net Assets | 9 Months Ended |
Sep. 30, 2019 | |
Notes to Financial Statements | |
Restricted Assets Disclosure [Text Block] | 8. Restricted net assets As a result of PRC laws and regulations, the Company’s PRC subsidiaries are restricted in their ability to transfer a portion of their net assets to the Company. As of December 31, 2018 September 30, 2019, nil $4,279, |
Note 9 - Employee Defined Contr
Note 9 - Employee Defined Contribution Plan | 9 Months Ended |
Sep. 30, 2019 | |
Notes to Financial Statements | |
Compensation and Employee Benefit Plans [Text Block] | 9. Employee defined contribution plan Full time employees of the Company in the PRC participate in a government mandated defined contribution plan, pursuant to which certain pension benefits, medical care, employee housing fund and other welfare benefits are provided to employees. Chinese labor regulations require that the Company’s PRC subsidiaries make contributions to the government for these benefits based on certain percentages of the employees’ salaries. The Company has no $12 $38 three nine September 30, 2018 $20 $59 three nine September 30, 2019, |
Note 10 - Net Loss Per Share
Note 10 - Net Loss Per Share | 9 Months Ended |
Sep. 30, 2019 | |
Notes to Financial Statements | |
Earnings Per Share [Text Block] | 10. Net loss per share Basic and diluted net loss per share attributable to ordinary shareholders was calculated as follows: Three months ended Nine months ended September 30, September 30, 2018 2019 2018 2019 (Unaudited) (Unaudited) (Unaudited) (Unaudited) Numerator: Net loss attributable to BeyondSpring Inc. — basic and diluted $ (14,930 ) $ (9,367 ) $ (40,752 ) $ (24,012 ) Denominator: Weighted average number of ordinary shares outstanding—basic and diluted 22,951,635 25,309,776 22,547,990 23,819,453 Net loss per share —basic and diluted $ (0.65 ) $ (0.37 ) $ (1.81 ) $ (1.01 ) The effects of restricted shares and share options were excluded from the calculation of diluted earnings per share as their effect would have been anti-dilutive during the three nine September 30, 2018 2019. |
Note 11 - Lease
Note 11 - Lease | 9 Months Ended |
Sep. 30, 2019 | |
Notes to Financial Statements | |
Lessee, Operating Leases [Text Block] | 11. Lease The Company has operating lease for offices in the United States and China with remaining lease term of approximately 4.3 0.9 not $106 $316 three nine September 30, 2018 $198 $595 three nine September 30, 2019, Supplemental balance sheet information related to leases was as follows: As of September 30, 2019 $ Operating lease ROU asset 2,704 Current portion of operating lease liabilities 542 Operating lease liabilities 2,091 Total lease liabilities 2,633 Maturities of operating lease liabilities are as follows: $ Three months ending December 31, 2019 87 Year ending December 31, 2020 780 Year ending December 31, 2021 786 Year ending December 31, 2022 789 Year ending December 31, 2023 793 Total lease payments 3,235 Less imputed interest (602 ) Present value of lease liabilities 2,633 Other supplemental information related to leases is summarized below: Nine months ended September 30, 2019 $ Operating cash flows used in operating lease 620 As of September 30, 2019 Weighted average remaining lease term (years) 4.23 Weighted average discount rate 8.45 % The Company adopted the Lease ASUs effective January 1, 2019 not December 31, 2018, $ Year ending December 31, 2019 792 Year ending December 31, 2020 798 Year ending December 31, 2021 786 Year ending December 31, 2022 789 Year ending December 31, 2023 793 Total 3,958 |
Note 12 - Share-based Compensat
Note 12 - Share-based Compensation | 9 Months Ended |
Sep. 30, 2019 | |
Notes to Financial Statements | |
Share-based Payment Arrangement [Text Block] | 12. Share-based compensation During the nine September 30, 2019, 100,000 50,000 50,000 The following table summarizes total share-based compensation expense recognized for the three nine September 30, 2018 2019: Three months ended Nine months ended September 30, September 30, 2018 2019 2018 2019 (Unaudited) (Unaudited) (Unaudited) (Unaudited) $ $ $ $ Research and development 640 125 6,491 502 General and administrative 208 337 (450 ) 1,248 Total 848 462 6,041 1,750 |
Note 13 - Subsequent Event
Note 13 - Subsequent Event | 9 Months Ended |
Sep. 30, 2019 | |
Notes to Financial Statements | |
Subsequent Events [Text Block] | 13. Subsequent event In October 2019, 1,851,852 $13.50 $25,000. November 2019, one 57,144 $13.50 $771. In October 2019, three $2,537 |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 9 Months Ended |
Sep. 30, 2019 | |
Accounting Policies [Abstract] | |
Consolidation, Policy [Policy Text Block] | Basis of consolidation The unaudited interim condensed consolidated financial statements include the financial statements of the Company and its subsidiaries. All significant intercompany transactions and balances between the Company and its subsidiaries are eliminated upon consolidation. |
Going Concern, Policy [Policy Text Block} | Going concern According to Accounting Standards Codification (“ASC”) 205 40, Presentation of Financial Statements - Going Concern 205 40” one not not 1 one 2 one The Company has incurred operating losses and negative cash flows from operations since inception. To date, the Company has no $25,271 nine September 30, 2019 $202,772 September 30, 2019. $35,480 nine September 30, 2019. September 30, 2019, $21,872 $24,678 In October November 2019, $25,771 Based on the Company’s cash on hand at September 30, 2019 October November 2019 not one |
Use of Estimates, Policy [Policy Text Block] | Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these financial statements include, but are not |
Government Grants [Policy Text Block] | Government grants Government grants relating to assets are recognized in the consolidated balance sheets upon receipt and amortized as other income over the weighted average useful life of the related assets. Government grants relating to income that involves no |
Fair Value of Financial Instruments, Policy [Policy Text Block] | Fair value measurements The Company applies ASC 820, Fair Value Measurements and Disclosures 820” 820 ASC 820 three • Level 1— • Level 2— • Level 3— no ASC 820 three 1 2 3 Financial instruments of the Company primarily include cash, due from related parties, due to related parties, accounts payable and long-term loans. Except for the long-term loans, the carrying values of these financial instruments approximated their fair value due to their short term nature as of December 31, 2018 September 30, 2019. As of September 30, 2019, $1,399, $1,338. 2 |
Lessee, Leases [Policy Text Block] | Leases The Company determines if an arrangement is a lease at inception. The Company has lease agreements with lease and non-lease components, which are accounted for as a single lease component based on the Company’s policy election to combine lease and non-lease components for its leases. Leases are classified as operating or finance leases in accordance with the recognition criteria in ASC 842 20 25. September 30, 2019. not At the commencement date of a lease, the Company determines the classification of the lease based on the relevant factors present and records right-of-use (“ROU”) assets and lease liabilities. ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. ROU assets and lease liabilities are calculated as the present value of the lease payments not not not may Operating leases are included in operating lease right-of-use assets and lease liabilities on the condensed consolidated balance sheets. Lease liabilities that become due within one Leases with an initial lease term of 12 not |
New Accounting Pronouncements, Policy [Policy Text Block] | Recent accounting pronouncements New accounting standard which have been implemented In February 2016, No. 2016 2, Leases 2018 1, Land Easement Practical Expedient 2018 10, Codification Improvements to Topic 842, 2016 2; 2018 11, Leases (Topic 842 2018 20, Leases (Topic 842 2019 1, Leases (Topic 842 12 December 15, 2018, not The Company adopted the new standard effective January 1, 2019 not not $3,169, $3,188 $19. not In June 2018, 2018 7, Compensation—Stock Compensation (Topic 718 2018 7” 718 718 December 15, 2018. no Impact of adopted accounting standards The cumulative effect of changes made to the Company’s condensed consolidated balance sheet as of January 1, 2019 Balance at Adjustments Balance at December 31, due to January 1, 2018 Lease ASUs 2019 $ $ $ Assets: Prepaid expenses and other current assets 292 (19 ) 273 Operating lease right-of-use assets - 3,188 3,188 Liabilities: Current portion of operating lease liabilities - 605 605 Operating lease liabilities - 2,564 2,564 |
Note 1 - Nature of the Busine_2
Note 1 - Nature of the Business and Basis of Preparation (Tables) | 9 Months Ended |
Sep. 30, 2019 | |
Notes Tables | |
Schedule of Subsidiaries [Table Text Block] | Name of company Place of incorporation Date of incorporation Percentage of ownership by the Company Principal activities BeyondSpring Delaware, Pharmaceuticals Inc. United States of America (“U.S.”) June 18, 2013 100% Clinical trial activities BeyondSpring Ltd. BVI December 3, 2014 100% Holding company BeyondSpring (HK) Limited Hong Kong January 13, 2015 100% Holding company Wanchun Biotechnology Limited BVI April 1, 2015 100% Holding company Wanchun Biotechnology The People’s Republic of China (Shenzhen) Ltd. (“PRC”) April 23, 2015 100% Holding company Wanchunbulin PRC May 6, 2015 57.97% Clinical trial activities BeyondSpring Pharmaceuticals Australia PTY Ltd. (“BeyondSpring Australia”) Australia March 3, 2016 100% Clinical trial activities Beijing Wanchun Pharmaceutical Technology Ltd. (“Beijing Wanchun”) PRC May 21, 2018 57.97% Clinical trial activities SEED BVI June 25, 2019 100% Holding company |
Note 2 - Summary of Significa_2
Note 2 - Summary of Significant Accounting Policies (Tables) | 9 Months Ended |
Sep. 30, 2019 | |
Notes Tables | |
Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block] | Balance at Adjustments Balance at December 31, due to January 1, 2018 Lease ASUs 2019 $ $ $ Assets: Prepaid expenses and other current assets 292 (19 ) 273 Operating lease right-of-use assets - 3,188 3,188 Liabilities: Current portion of operating lease liabilities - 605 605 Operating lease liabilities - 2,564 2,564 |
Note 3 - Property and Equipme_2
Note 3 - Property and Equipment, Net (Tables) | 9 Months Ended |
Sep. 30, 2019 | |
Notes Tables | |
Property, Plant and Equipment [Table Text Block] | December 31, September 30, 2018 2019 $ $ (Unaudited) Office equipment 143 145 Laboratory equipment 111 112 Motor vehicles 23 23 Leasehold improvements 109 102 386 382 Less: accumulated depreciation (104 ) (165 ) Property and equipment, net 282 217 |
Note 7 - Equity (Deficit) (Tabl
Note 7 - Equity (Deficit) (Tables) | 9 Months Ended |
Sep. 30, 2019 | |
Notes Tables | |
Schedule of Stockholders Equity [Table Text Block] | BeyondSpring Inc.’s shareholders Accumulated Additional other Non Total Ordinary share paid-in Accumulated comprehensive Subtotal controlling equity Shares Amount capital deficit (loss) gain interests (deficit) $ $ $ $ $ $ $ Balances at January 1, 2019 (audited) 23,184,612 2 170,950 (178,760 ) 42 (7,766 ) (1,616 ) (9,382 ) Issuance of ordinary shares 2,679,578 1 44,956 - - 44,957 - 44,957 Capital contribution from noncontrolling interests - - 5,941 - - 5,941 4,142 10,083 Share-based compensation 100,000 - 1,750 - - 1,750 - 1,750 Capital contribution shared by noncontrolling interests - - (578 ) - - (578 ) 578 - Foreign currency translation adjustment gain (loss) - - - - 183 183 (39 ) 144 Net loss - - - (24,012 ) - (24,012 ) (1,259 ) (25,271 ) Balances at September 30, 2019 (unaudited) 25,964,190 3 223,019 (202,772 ) 225 20,475 1,806 22,281 Balances at January 1, 2018 (audited) 22,530,702 2 151,147 (123,891 ) (182 ) 27,076 960 28,036 Issuance of ordinary shares 739,095 - 13,245 - - 13,245 - 13,245 Share-based compensation (95,000 ) - 6,039 - - 6,039 2 6,041 Foreign currency translation adjustment gain - - - - 237 237 34 271 Net loss - - - (40,752 ) - (40,752 ) (2,011 ) (42,763 ) Balances at September 30, 2018 (unaudited) 23,174,797 2 170,431 (164,643 ) 55 5,845 (1,015 ) 4,830 |
Note 10 - Net Loss Per Share (T
Note 10 - Net Loss Per Share (Tables) | 9 Months Ended |
Sep. 30, 2019 | |
Notes Tables | |
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] | Three months ended Nine months ended September 30, September 30, 2018 2019 2018 2019 (Unaudited) (Unaudited) (Unaudited) (Unaudited) Numerator: Net loss attributable to BeyondSpring Inc. — basic and diluted $ (14,930 ) $ (9,367 ) $ (40,752 ) $ (24,012 ) Denominator: Weighted average number of ordinary shares outstanding—basic and diluted 22,951,635 25,309,776 22,547,990 23,819,453 Net loss per share —basic and diluted $ (0.65 ) $ (0.37 ) $ (1.81 ) $ (1.01 ) |
Note 11 - Lease (Tables)
Note 11 - Lease (Tables) | 9 Months Ended |
Sep. 30, 2019 | |
Notes Tables | |
Operating Lease, Supplement Balance Sheet Information [Table Text Block] | As of September 30, 2019 $ Operating lease ROU asset 2,704 Current portion of operating lease liabilities 542 Operating lease liabilities 2,091 Total lease liabilities 2,633 |
Lessee, Operating Lease, Liability, Maturity [Table Text Block] | $ Three months ending December 31, 2019 87 Year ending December 31, 2020 780 Year ending December 31, 2021 786 Year ending December 31, 2022 789 Year ending December 31, 2023 793 Total lease payments 3,235 Less imputed interest (602 ) Present value of lease liabilities 2,633 |
Lease, Cost [Table Text Block] | Nine months ended September 30, 2019 $ Operating cash flows used in operating lease 620 As of September 30, 2019 Weighted average remaining lease term (years) 4.23 Weighted average discount rate 8.45 % |
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] | $ Year ending December 31, 2019 792 Year ending December 31, 2020 798 Year ending December 31, 2021 786 Year ending December 31, 2022 789 Year ending December 31, 2023 793 Total 3,958 |
Note 12 - Share-based Compens_2
Note 12 - Share-based Compensation (Tables) | 9 Months Ended |
Sep. 30, 2019 | |
Notes Tables | |
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] | Three months ended Nine months ended September 30, September 30, 2018 2019 2018 2019 (Unaudited) (Unaudited) (Unaudited) (Unaudited) $ $ $ $ Research and development 640 125 6,491 502 General and administrative 208 337 (450 ) 1,248 Total 848 462 6,041 1,750 |
Note 1 - Nature of the Busine_3
Note 1 - Nature of the Business and Basis of Preparation (Details Textual) $ in Thousands, ¥ in Millions | May 21, 2019USD ($) | Jul. 03, 2019USD ($) | Jul. 03, 2019CNY (¥) | Nov. 30, 2019USD ($) | Jul. 31, 2019USD ($)shares | Sep. 30, 2019USD ($) | Sep. 30, 2019CNY (¥) | Sep. 30, 2019USD ($) | Sep. 30, 2018USD ($) |
Proceeds from Issuance of Common Stock | $ 25,771 | $ 44,957 | $ 14,000 | ||||||
Wanchunbulin [Member] | |||||||||
Investment Agreement Amount | $ 14,537 | ¥ 100 | |||||||
Proceeds From Noncontrolling Interest, Percent | 4.76% | 4.76% | |||||||
Proceeds From Noncontrolling Interest | $ 10,083 | ¥ 70 | |||||||
Jefferies [Member] | |||||||||
Stock Issued During Period, Shares, New Issues | shares | 620,753 | ||||||||
Proceeds from Issuance of Common Stock | $ 13,023 | ||||||||
Jefferies [Member] | Maximum [Member] | |||||||||
Aggregate Offering Price, Sales Agreement | $ 30,000 |
Note 1 - Nature of the Busine_4
Note 1 - Nature of the Business and Basis of Preparation - Schedule of Subsidiaries (Details) | Sep. 30, 2019 |
BeyondSpring Pharmaceuticals Inc. [Member] | |
Equity method investment, ownership percentage | 100.00% |
BeyondSpring Ltd. [Member] | |
Equity method investment, ownership percentage | 100.00% |
BeyondSpring HK [Member] | |
Equity method investment, ownership percentage | 100.00% |
Wanchun Biotechnology Limited [Member] | |
Equity method investment, ownership percentage | 100.00% |
Wanchun Biotechnology (Shenzhen) Ltd. [Member] | |
Equity method investment, ownership percentage | 100.00% |
Dalian Wanchunbulin Pharmaceuticals Ltd. (“Wanchunbulin”) [Member] | |
Equity method investment, ownership percentage | 57.97% |
BeyondSpring Pharmaceuticals Australia PTY Ltd. (“BeyondSpring Australia”) [Member] | |
Equity method investment, ownership percentage | 100.00% |
Beijing Wanchun Pharmaceutical Technology Ltd. [Member] | |
Equity method investment, ownership percentage | 57.97% |
Seed [Member] | |
Equity method investment, ownership percentage | 100.00% |
Note 2 - Summary of Significa_3
Note 2 - Summary of Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands | 2 Months Ended | 3 Months Ended | 9 Months Ended | ||||
Nov. 30, 2019 | Sep. 30, 2019 | Sep. 30, 2018 | Sep. 30, 2019 | Sep. 30, 2018 | Jan. 01, 2019 | Dec. 31, 2018 | |
Revenue from Contract with Customer, Including Assessed Tax | $ 0 | ||||||
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total | (9,824) | $ (15,895) | (25,271) | (42,763) | |||
Retained Earnings (Accumulated Deficit), Ending Balance | (202,772) | (202,772) | $ (178,760) | ||||
Net Cash Provided by (Used in) Operating Activities, Total | (35,480) | (31,635) | |||||
Net Current Assets | 21,872 | 21,872 | |||||
Cash, Ending Balance | 24,678 | 24,678 | |||||
Proceeds from Issuance of Common Stock | $ 25,771 | 44,957 | $ 14,000 | ||||
Long-term Debt, Total | 1,399 | 1,399 | |||||
Long-term Debt, Fair Value | 1,338 | 1,338 | |||||
Operating Lease, Liability, Total | 2,633 | 2,633 | |||||
Operating Lease, Right-of-Use Asset | $ 2,704 | $ 2,704 | $ 3,188 | ||||
Accounting Standards Update 2016-02 [Member] | |||||||
Operating Lease, Liability, Total | 3,169 | ||||||
Operating Lease, Right-of-Use Asset | 3,188 | ||||||
Prepaid Rent | $ (19) |
Note 2 - Summary of Significa_4
Note 2 - Summary of Significant Accounting Policies - Impact of Adopted Accounting Standards (Details) - USD ($) $ in Thousands | Sep. 30, 2019 | Jan. 01, 2019 | Dec. 31, 2018 |
Prepaid expenses and other current assets | $ 362 | $ 273 | $ 292 |
Operating lease right-of-use assets | 2,704 | 3,188 | |
Current portion of operating lease liabilities | 542 | 605 | |
Operating lease liabilities | $ 2,091 | 2,564 | |
Accounting Standards Update 2016-02 [Member] | |||
Prepaid expenses and other current assets | (19) | ||
Operating lease right-of-use assets | 3,188 | ||
Current portion of operating lease liabilities | 605 | ||
Operating lease liabilities | $ 2,564 |
Note 3 - Property and Equipme_3
Note 3 - Property and Equipment, Net (Details Textual) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2019 | Sep. 30, 2018 | Sep. 30, 2019 | Sep. 30, 2018 | |
Depreciation, Total | $ 21 | $ 9 | $ 61 | $ 29 |
Note 3 - Property and Equipme_4
Note 3 - Property and Equipment, Net - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands | Sep. 30, 2019 | Dec. 31, 2018 |
Property, plant, and equipment, gross | $ 382 | $ 386 |
Less: accumulated depreciation | (165) | (104) |
Property and equipment, net | 217 | 282 |
Office Equipment [Member] | ||
Property, plant, and equipment, gross | 145 | 143 |
Laboratory Equipment [Member] | ||
Property, plant, and equipment, gross | 112 | 111 |
Automobiles [Member] | ||
Property, plant, and equipment, gross | 23 | 23 |
Leasehold Improvements [Member] | ||
Property, plant, and equipment, gross | $ 102 | $ 109 |
Note 4 - Long-term Loans (Detai
Note 4 - Long-term Loans (Details Textual) $ in Thousands, ¥ in Millions | Mar. 28, 2019USD ($) | Sep. 30, 2019USD ($) | Mar. 28, 2019CNY (¥) | Jan. 21, 2019USD ($) | Jan. 21, 2019CNY (¥) |
Long-term Debt, Total | $ 1,399 | ||||
Loan Arrangement with Third Party [Member] | |||||
Long-term Debt, Total | $ 1,493 | ¥ 10 | |||
Debt Instrument, Interest Rate, Stated Percentage | 15.00% | 15.00% | |||
Term Loan [Member] | China Construction Bank [Member] | |||||
Long-term Debt, Total | $ 1,493 | ¥ 10 | |||
Debt Instrument, Term | 3 years | ||||
Term Loan [Member] | China Construction Bank [Member] | Three Yearr Loan Interest Rate Quoted by People's Bank of China [Member] | |||||
Debt Instrument, Annual Interest Rate Based on Variable Rate | 120.00% |
Note 5 - Related Party Transa_2
Note 5 - Related Party Transactions (Details Textual) $ in Thousands, ¥ in Millions | 1 Months Ended | ||||||
Apr. 30, 2019USD ($) | Feb. 28, 2019USD ($) | Jul. 15, 2019USD ($) | Jul. 15, 2019CNY (¥) | Apr. 26, 2019USD ($) | Mar. 31, 2019USD ($) | Dec. 31, 2018USD ($) | |
Debt Guaranteed by Founder [Member] | Shenzhen Sangel Zhichuang Investment Co Ltd [Member] | |||||||
Debt Instrument, Face Amount | $ 1,000 | ||||||
Debt Instrument, Interest Rate, Stated Percentage | 15.00% | ||||||
Proceeds from Issuance of Debt | $ 1,000 | ||||||
Interest Free Loan [Member] | Wanchun Biotechnology (Shenzhen) Ltd. [Member] | |||||||
Financing Raised From Noncontrolling Shareholder | $ 1,978 | ¥ 13.6 | |||||
Interest Free Loan [Member] | Chief Medical Officer [Member] | |||||||
Due from Related Parties, Total | $ 481 | ||||||
Proceeds from Collection of Notes Receivable | $ 100 | ||||||
Interest Free Loan [Member] | Chief Executive Officer, Chief Regulatory Officer, International Finance Manager [Member] | |||||||
Due to Related Parties, Total | $ 350 |
Note 6 - Income Taxes (Details
Note 6 - Income Taxes (Details Textual) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2019 | Sep. 30, 2018 | Sep. 30, 2019 | Sep. 30, 2018 | |
Income Tax Expense (Benefit), Total | $ 0 | $ 0 | $ 0 | $ 0 |
Note 7 - Equity (Deficit) - Sch
Note 7 - Equity (Deficit) - Schedule of Stockholders' Equity (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2019 | Sep. 30, 2018 | Sep. 30, 2019 | Sep. 30, 2018 | |
Balances | $ (9,382) | $ 28,036 | ||
Issuance of ordinary shares | 44,957 | 13,245 | ||
Capital contribution from noncontrolling interests | 10,083 | |||
Share-based compensation | 1,750 | |||
Capital injection shared by Noncontrolling interests | ||||
Foreign currency translation adjustment gain | $ 113 | $ 167 | 144 | 271 |
Net loss | (9,824) | (15,895) | (25,271) | (42,763) |
Share-based compensation | 6,041 | |||
Balances | $ 22,281 | $ 4,830 | $ 22,281 | $ 4,830 |
Common Stock [Member] | ||||
Balances (in shares) | 23,184,612 | 22,530,702 | ||
Balances | $ 2 | $ 2 | ||
Issuance of ordinary shares (in shares) | 2,679,578 | 739,095 | ||
Issuance of ordinary shares | $ 1 | |||
Capital contribution from noncontrolling interests | ||||
Share-based compensation (in shares) | 100,000 | (95,000) | ||
Share-based compensation | ||||
Capital injection shared by Noncontrolling interests | ||||
Foreign currency translation adjustment gain | ||||
Net loss | ||||
Share-based compensation | ||||
Balances (in shares) | 25,964,190 | 23,174,797 | 25,964,190 | 23,174,797 |
Balances | $ 3 | $ 2 | $ 3 | $ 2 |
Additional Paid-in Capital [Member] | ||||
Balances | 170,950 | 151,147 | ||
Issuance of ordinary shares | 44,956 | 13,245 | ||
Capital contribution from noncontrolling interests | 5,941 | |||
Share-based compensation | 1,750 | |||
Capital injection shared by Noncontrolling interests | (578) | |||
Foreign currency translation adjustment gain | ||||
Net loss | ||||
Share-based compensation | 6,039 | |||
Balances | 223,019 | 170,431 | 223,019 | 170,431 |
Retained Earnings [Member] | ||||
Balances | (178,760) | (123,891) | ||
Issuance of ordinary shares | ||||
Capital contribution from noncontrolling interests | ||||
Share-based compensation | ||||
Capital injection shared by Noncontrolling interests | ||||
Foreign currency translation adjustment gain | ||||
Net loss | (24,012) | (40,752) | ||
Share-based compensation | ||||
Balances | (202,772) | (164,643) | (202,772) | (164,643) |
AOCI Attributable to Parent [Member] | ||||
Balances | 42 | (182) | ||
Issuance of ordinary shares | ||||
Capital contribution from noncontrolling interests | ||||
Share-based compensation | ||||
Capital injection shared by Noncontrolling interests | ||||
Foreign currency translation adjustment gain | 183 | 237 | ||
Net loss | ||||
Share-based compensation | ||||
Balances | 225 | 55 | 225 | 55 |
Parent [Member] | ||||
Balances | (7,766) | 27,076 | ||
Issuance of ordinary shares | 44,957 | 13,245 | ||
Capital contribution from noncontrolling interests | 5,941 | |||
Share-based compensation | 1,750 | |||
Capital injection shared by Noncontrolling interests | (578) | |||
Foreign currency translation adjustment gain | 183 | 237 | ||
Net loss | (24,012) | (40,752) | ||
Share-based compensation | 6,039 | |||
Balances | 20,475 | 5,845 | 20,475 | 5,845 |
Noncontrolling Interest [Member] | ||||
Balances | (1,616) | 960 | ||
Issuance of ordinary shares | ||||
Capital contribution from noncontrolling interests | 4,142 | |||
Share-based compensation | ||||
Capital injection shared by Noncontrolling interests | 578 | |||
Foreign currency translation adjustment gain | (39) | 34 | ||
Net loss | (1,259) | (2,011) | ||
Share-based compensation | 2 | |||
Balances | $ 1,806 | $ (1,015) | $ 1,806 | $ (1,015) |
Note 8 - Restricted Net Assets
Note 8 - Restricted Net Assets (Details Textual) $ in Thousands | Sep. 30, 2019USD ($) |
Restricted Net Assets | $ 4,279 |
Note 9 - Employee Defined Con_2
Note 9 - Employee Defined Contribution Plan (Details Textual) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2019 | Sep. 30, 2018 | Sep. 30, 2019 | Sep. 30, 2018 | |
Defined Contribution Plan, Cost | $ 20 | $ 12 | $ 59 | $ 38 |
Note 10 - Net Loss Per Share -
Note 10 - Net Loss Per Share - Basic and Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2019 | Sep. 30, 2018 | Sep. 30, 2019 | Sep. 30, 2018 | |
Net loss attributable to BeyondSpring Inc. — basic and diluted | $ (9,367) | $ (14,930) | $ (24,012) | $ (40,752) |
Weighted average number of ordinary shares outstanding — basic and diluted (in shares) | 25,309,776 | 22,951,635 | 23,819,453 | 22,547,990 |
Net loss per share —basic and diluted (in dollars per share) | $ (0.37) | $ (0.65) | $ (1.01) | $ (1.81) |
Note 11 - Lease (Details Textua
Note 11 - Lease (Details Textual) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2019 | Sep. 30, 2018 | Sep. 30, 2019 | Sep. 30, 2018 | |
Operating Lease, Expense | $ 198 | $ 106 | $ 595 | $ 316 |
UNITED STATES | ||||
Lessee, Operating Lease, Remaining Lease Term | 4 years 109 days | |||
CHINA | ||||
Lessee, Operating Lease, Remaining Lease Term | 328 days |
Note 11 - Lease - Supplement Ba
Note 11 - Lease - Supplement Balance Sheet Information Related to Leases (Details) - USD ($) $ in Thousands | Sep. 30, 2019 | Jan. 01, 2019 | Dec. 31, 2018 |
Operating Lease, Right-of-Use Asset | $ 2,704 | $ 3,188 | |
Current portion of operating lease liabilities | 542 | 605 | |
Operating lease liabilities | 2,091 | $ 2,564 | |
Total lease liabilities | $ 2,633 |
Note 11 - Lease - Maturities of
Note 11 - Lease - Maturities of Lease Liabilities (Details) $ in Thousands | Sep. 30, 2019USD ($) |
Three months ending December 31, 2019 | $ 87 |
Year ending December 31, 2020 | 780 |
Year ending December 31, 2021 | 786 |
Year ending December 31, 2022 | 789 |
Year ending December 31, 2023 | 793 |
Total lease payments | 3,235 |
Less imputed interest | (602) |
Present value of lease liabilities | $ 2,633 |
Note 11 - Lease - Operating Lea
Note 11 - Lease - Operating Lease Disclosure (Details) $ in Thousands | 9 Months Ended |
Sep. 30, 2019USD ($) | |
Operating cash flows used in operating lease | $ 620 |
Weighted average remaining lease term (Year) | 4 years 83 days |
Weighted average discount rate | 8.45% |
Note 11 - Lease - Future Minimu
Note 11 - Lease - Future Minimum Lease Payments Under Operating Lease (Details) $ in Thousands | Dec. 31, 2018USD ($) |
Year ending December 31, 2019 | $ 792 |
Year ending December 31, 2020 | 798 |
Year ending December 31, 2021 | 786 |
Year ending December 31, 2022 | 789 |
Year ending December 31, 2023 | 793 |
Total | $ 3,958 |
Note 12 - Share-based Compens_3
Note 12 - Share-based Compensation (Details Textual) | 9 Months Ended |
Sep. 30, 2019shares | |
Restricted Stock [Member] | |
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period | 100,000 |
Restricted Stock Contains Service Vesting Conditions [Member] | |
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period | 50,000 |
Restricted Stock Contain Performance Conditions [Member] | |
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period | 50,000 |
Note 12 - Share-based Compens_4
Note 12 - Share-based Compensation - Share-based Compensation Expense (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2019 | Sep. 30, 2018 | Sep. 30, 2019 | Sep. 30, 2018 | |
Allocated Share-based Compensation Expense | $ 462 | $ 848 | $ 1,750 | $ 6,041 |
Research and Development Expense [Member] | ||||
Allocated Share-based Compensation Expense | 125 | 640 | 502 | 6,491 |
General and Administrative Expense [Member] | ||||
Allocated Share-based Compensation Expense | $ 337 | $ 208 | $ 1,248 | $ (450) |
Note 13 - Subsequent Event (Det
Note 13 - Subsequent Event (Details Textual) - USD ($) $ / shares in Units, $ in Thousands | 1 Months Ended | 2 Months Ended | 9 Months Ended | ||
Nov. 30, 2019 | Oct. 31, 2019 | Nov. 30, 2019 | Sep. 30, 2019 | Sep. 30, 2018 | |
Proceeds from Issuance of Common Stock | $ 25,771 | $ 44,957 | $ 14,000 | ||
Proceeds from Related Party Debt | $ 3,328 | ||||
Subsequent Event [Member] | Dalian Wanchun Biotechnology Co., Ltd. [Member] | |||||
Proceeds from Related Party Debt | $ 2,537 | ||||
Subsequent Event [Member] | Underwriters [Member] | |||||
Stock Issued During Period, Shares, New Issues | 57,144 | ||||
Shares Issued, Price Per Share | $ 13.50 | $ 13.50 | |||
Proceeds from Issuance of Common Stock | $ 771 | ||||
Public Offering [Member] | Subsequent Event [Member] | |||||
Stock Issued During Period, Shares, New Issues | 1,851,852 | ||||
Shares Issued, Price Per Share | $ 13.50 | ||||
Proceeds from Issuance of Common Stock | $ 25,000 |